SLU-PP-332: A Comprehensive Research Monograph

Introduction

SLU-PP-332 is a synthetic small molecule developed as a pharmacological exercise mimetic — a compound designed to activate the molecular programs normally triggered by physical exercise. The name derives from its institutional origin: Saint Louis University Pharmacological Probe 332. It was developed by a research team led by Thomas P. Burris, Bahaa Elgendy, and John K. Walker at Saint Louis University through a rational drug design approach, with the goal of creating an agonist for the estrogen-related receptors (ERRs), a subfamily of orphan nuclear receptors that play central roles in energy metabolism and exercise adaptation. . . ().

The concept of exercise mimetics arises from a straightforward observation: physical exercise is among the most effective interventions known for preventing and treating chronic diseases, including obesity, type 2 diabetes, cardiovascular disease, neurodegeneration, and cancer. However, many individuals cannot exercise due to injury, disability, age-related frailty, or chronic illness. A compound that could recapitulate the metabolic benefits of exercise — increased mitochondrial function, enhanced fatty acid oxidation, improved endurance, and reduced fat mass — without requiring physical activity would have profound therapeutic implications.

The exercise mimetic concept was established in a landmark 2008 study by Narkar, Downes, Evans, and colleagues, who demonstrated that GW501516 (a PPARdelta agonist) and AICAR (an AMPK activator) could enhance running endurance in mice. . . (). SLU-PP-332 represents a new generation of exercise mimetics operating through a distinct molecular target: the ERR nuclear receptor family. In 2023, Billon and colleagues published the first comprehensive characterization of SLU-PP-332, demonstrating that it induces an acute aerobic exercise gene program in skeletal muscle, increases oxidative muscle fibers, and enhances exercise endurance in mice — all through activation of ERRalpha. . . (). Subsequent studies have expanded the compound’s demonstrated efficacy to models of obesity, metabolic syndrome, heart failure, kidney aging, and sarcopenia, establishing SLU-PP-332 as a versatile research tool for investigating the therapeutic potential of ERR activation.

Unlike the peptides that constitute the majority of this research catalog, SLU-PP-332 is a small molecule belonging to the acyl hydrazone chemical class. It is included alongside peptides because of its direct relevance to the metabolic, mitochondrial, and muscle physiology research areas served by the catalog, and because its mechanism of action — activation of nuclear receptors that regulate mitochondrial biogenesis and oxidative metabolism — intersects extensively with the pathways modulated by research peptides such as MOTS-c, AOD-9604, and tesamorelin.

Molecular Structure & Properties

SLU-PP-332 is chemically designated as 4-hydroxy-N’-(2-naphthylidene)benzohydrazide. It is a synthetic acyl hydrazone derivative developed through structure-based modification of GSK4716, a previously identified ERRbeta/gamma-selective agonist.

The design of SLU-PP-332 represents a notable achievement in nuclear receptor pharmacology. The ERRs had been considered intractable drug targets because ERRalpha possesses a collapsed ligand binding pocket and because numerous high-throughput screening campaigns and structure-based design efforts had failed to produce ERRalpha agonists. Using the X-ray crystal structure of ERRgamma bound to GSK4716 (PDB: 2GPP) as a starting point, the researchers replaced the isopropyl phenyl group of GSK4716 with a naphthalene moiety, hypothesizing that the larger aromatic system could engage in pi-pi stacking interactions with Phe328, a residue unique to ERRalpha. This modification gained approximately 50-fold ERRalpha potency compared to the parent GSK4716 scaffold, yielding a pan-agonist with the highest potency at ERRalpha — the first synthetic compound to achieve this. . . ().

Direct binding of SLU-PP-332 to ERRalpha was confirmed through limited proteolysis assays, where the compound dose-dependently protected fragments of the ERRalpha ligand binding domain from chymotrypsin digestion, consistent with a drug-induced conformational change. Differential scanning fluorimetry further confirmed direct binding, demonstrating dose-dependent increases in the thermal stability of purified ERRalpha protein. . . ().

Mechanism of Action

SLU-PP-332 exerts its biological effects by binding to and activating all three isoforms of the estrogen-related receptor family — ERRalpha, ERRbeta, and ERRgamma — with preferential potency at ERRalpha. These orphan nuclear receptors are constitutively active transcription factors that regulate a broad network of genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and the tricarboxylic acid (TCA) cycle. By pharmacologically enhancing the already-active transcriptional output of these receptors, SLU-PP-332 amplifies the metabolic programs that are normally upregulated by physical exercise.

ERR Activation and Downstream Signaling

The estrogen-related receptors were the first orphan nuclear receptors to be identified. Despite their name, they do not bind estrogen or other steroid hormones — the designation reflects structural homology to estrogen receptors rather than shared ligand specificity. ERRs are highly expressed in tissues with high energy demand, including skeletal muscle, heart, brain, brown adipose tissue, and kidney. . . (). They function as constitutively active transcription factors, meaning they exhibit basal transcriptional activity without requiring a ligand. This constitutive activity is enhanced through recruitment of the PGC-1alpha (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) coactivator, which serves as a master regulator of mitochondrial biogenesis.

SLU-PP-332 binding to the ERR ligand binding domain induces a conformational change that further stabilizes the active conformation of the receptor, enhancing its transcriptional output above the already-elevated constitutive level. This pharmacological enhancement approximates the 1.5- to 2-fold increase in ERR transcriptional activity observed following exercise, making SLU-PP-332’s effects more physiologically aligned with normal exercise adaptation than the supra-physiological activation produced by experimental genetic overexpression models. . . ().

The DDIT4-Dependent Acute Aerobic Exercise Program

One of the most striking findings from SLU-PP-332 research is the compound’s ability to induce the DNA Damage Inducible Transcript 4 (DDIT4/REDD1) gene, which directs an acute aerobic exercise genetic signature. In the initial characterization study, DDIT4 was the most upregulated gene shared between quadriceps and gastrocnemius muscles following SLU-PP-332 treatment. DDIT4 is a gene that is transiently induced by short bouts of aerobic exercise and is responsible for orchestrating a downstream cascade of exercise-responsive gene expression. Mice deficient in DDIT4 display reduced mitochondrial respiration in skeletal muscle and impaired exercise capacity. . . ().

Critically, this effect is ERRalpha-dependent. Using primary myocytes derived from skeletal muscle-specific ERRalpha knockout mice, the researchers demonstrated that DDIT4 induction by SLU-PP-332 was completely abolished when ERRalpha was absent, while it remained intact in ERRgamma knockout myocytes. Furthermore, whole-animal studies confirmed that mice with muscle-specific ERRalpha deletion failed to show enhanced exercise endurance with SLU-PP-332 treatment, while ERRgamma-knockout mice retained the full drug response.

Comparison of the gene expression changes induced by SLU-PP-332 with datasets from mice subjected to acute aerobic treadmill exercise, and from human subjects after a single bout of cycling, revealed statistically significant overlap. Seventeen genes were shared between SLU-PP-332-treated mouse muscle and the mouse acute exercise dataset, including four of the top 10 upregulated genes in the DDIT4-dependent pathway. Eight genes were regulated across all three groups (SLU-PP-332, mouse exercise, and human exercise). . . ().

Tissue-Specific ERR Isoform Dependencies

An important nuance of SLU-PP-332’s mechanism is that different ERR isoforms mediate its effects in different tissues. In skeletal muscle, ERRalpha is the primary mediator of exercise endurance enhancement and DDIT4 induction. However, in the heart, ERRgamma appears to be the principal mediator of the compound’s cardioprotective effects, including the transcriptional activation of fatty acid metabolism genes and the maintenance of mitochondrial oxidative capacity during pressure overload-induced heart failure. . . (). This tissue-specific isoform dependency underscores the value of pan-ERR agonism — by activating all three receptors, SLU-PP-332 engages the appropriate isoform in each tissue context.

Recent work has also identified that ERR agonists regulate autophagy through TFEB (transcription factor EB), a master regulator of the autophagy-lysosome pathway. TFEB is a direct ERR target gene, and its induction by ERR agonists leads to increased expression of an array of TFEB target genes critical for autophagy stimulation. This mechanism is particularly relevant in the cardiac context, where autophagy maintenance is essential for cardiomyocyte homeostasis. . . ().

Research Applications

Exercise Endurance and Muscle Fiber Type Switching

The founding and most extensively studied application of SLU-PP-332 is as an exercise mimetic. In the initial characterization study, sedentary C57BL/6J mice treated with SLU-PP-332 (50 mg/kg, twice daily, intraperitoneal, for 7 days) and then subjected to exhaustive treadmill running were able to run approximately 70% longer and 45% farther than vehicle-treated controls. This enhancement was accompanied by histological changes in muscle: treated mice exhibited a more oxidative muscle phenotype with greater succinate dehydrogenase (SDH) staining, increased expression of oxidative phosphorylation complex proteins (Complex I NDUFB8 and Complex V ATP5A), elevated cytochrome c levels, and increased mitochondrial DNA content. Notably, SLU-PP-332 treatment induced a shift toward type IIa oxidative muscle fibers, as confirmed by immunohistochemistry and Myosin IIA protein expression. . . ().

A two-week treatment regimen also increased grip strength in addition to endurance, suggesting benefits for both aerobic and functional muscle capacity. These effects occurred without exercise training, establishing SLU-PP-332 as a true exercise mimetic that recapitulates physiological adaptations in sedentary animals.

Obesity and Metabolic Syndrome

A 2024 study in the Journal of Pharmacology and Experimental Therapeutics extended SLU-PP-332 research to mouse models of obesity and metabolic syndrome. Diet-induced obese (DIO) mice and genetically obese ob/ob mice were administered SLU-PP-332, and the effects on whole-body metabolism were assessed. The compound mimicked exercise-induced metabolic benefits, including increased energy expenditure and fatty acid oxidation. These effects were accompanied by decreased fat mass accumulation. Additionally, SLU-PP-332 effectively reduced obesity and improved insulin sensitivity in both models of metabolic syndrome, supporting the therapeutic relevance of ERR activation for metabolic disease. . . ().

These findings position ERR agonism as a potential pharmacological approach to obesity that works not by suppressing appetite (as GLP-1 receptor agonists do) but by increasing the body’s metabolic rate and capacity for fat oxidation — essentially shifting the metabolic phenotype toward that of an exercised individual.

Heart Failure and Cardioprotection

SLU-PP-332 has demonstrated significant cardioprotective effects in a pressure overload-induced heart failure model. Published in Circulation, this study showed that both SLU-PP-332 and its newer analog SLU-PP-915 significantly improved ejection fraction, ameliorated cardiac fibrosis, and increased survival in mice subjected to transaortic constriction. The mechanism involved broad transcriptional activation of metabolic genes, particularly those involved in fatty acid metabolism and mitochondrial function. Metabolomics analysis revealed substantial normalization of metabolic profiles in fatty acid/lipid and TCA/oxidative phosphorylation metabolites in treated hearts. . . ().

Genetic dependency experiments in this study demonstrated that ERRgamma is the main mediator of ERR agonism-induced cardioprotection, contrasting with the ERRalpha-dependent mechanism in skeletal muscle. ERR agonists also led to downregulation of cell cycle and development pathways, partially mediated through E2F1 in cardiomyocytes. These results provide direct pharmacologic evidence supporting further development of ERR agonists as novel heart failure therapeutics.

Aging Kidney Protection

A compelling study published in the American Journal of Pathology examined SLU-PP-332 in the context of kidney aging. The researchers first demonstrated that ERR expression declines in both aging human and mouse kidneys and is preserved in aging mice subjected to lifelong caloric restriction. Treatment of 21-month-old mice with SLU-PP-332 for 8 weeks remarkably reversed age-related increases in albuminuria, podocyte loss, mitochondrial dysfunction, and inflammatory cytokines. The anti-inflammatory effects were mediated through the cyclic GMP-AMP synthase-STING and STAT3 signaling pathways. Based on these findings, the authors described ERRs as “caloric restriction mimetics,” highlighting the overlap between ERR activation and the well-established protective effects of caloric restriction on aging tissues. . . ().

Sarcopenia and Age-Related Muscle Atrophy

A 2025 pilot study investigated SLU-PP-332 treatment in human primary myoblasts isolated from the skeletal muscle of physically inactive women undergoing hip arthroplasty. The inactive women’s muscle tissue showed significantly higher expression of the oxidative stress marker NOX4 alongside reduced levels of SIRT1, PGC-1alpha, ERRalpha, and the myokine FNDC5 (irisin precursor). Treatment with SLU-PP-332 reversed this profile, promoting downregulation of NOX4 and upregulation of SIRT1, PGC-1alpha, ERRalpha, FNDC5, Akt, and the anti-apoptotic factor Bcl-2. The compound reduced cytotoxicity, oxidative stress, and markers of cellular senescence while increasing levels of reduced glutathione. Furthermore, SLU-PP-332 treatment promoted abundant myotube formation, positively influencing cell differentiation. . . ().

These results are particularly significant because they represent the first use of SLU-PP-332 in human-derived cells from a clinically relevant population — elderly, inactive individuals at risk for sarcopenia. The ability of ERR activation to restore the metabolic and regenerative profile of aged, inactive human muscle cells supports the potential utility of this target for combating age-related muscle decline.

Pharmacokinetics & Stability

The pharmacokinetic properties of SLU-PP-332 have been characterized through studies in mice using mass spectrometric analysis of plasma and tissue concentrations.

Absorption and Distribution

Following intraperitoneal administration at 30 mg/kg, SLU-PP-332 achieves peak concentrations of approximately 0.6 micromolar in skeletal muscle and 0.2 micromolar in plasma at the 2-hour time point. The higher muscle-to-plasma ratio suggests favorable distribution to the target tissue, which is consistent with the compound’s demonstrated efficacy in modulating skeletal muscle gene expression and physiology. . . ().

A critical limitation of SLU-PP-332 is its lack of oral bioavailability. All in vivo studies have utilized intraperitoneal injection as the route of administration. This limitation prompted the development of SLU-PP-915, a structurally distinct pan-ERR agonist with confirmed oral bioavailability that maintains comparable exercise mimetic activity when administered orally, adjusted for systemic exposure. . . ().

Metabolism

Two independent 2026 studies have characterized the in vitro metabolic transformation products of SLU-PP-332 using human liver microsomes (HLMs) and human liver S9 fractions. Moller, Krug, and Thevis identified 9 metabolites consisting of 6 Phase I metabolites and 3 Phase II conjugates. . . (). A complementary study by Avliyakulov, Sobolevsky, and Ahrens identified 22 metabolites in total, including 5 monohydroxylated, 3 dihydroxylated, and 4 reduced dihydroxylated Phase I products, along with glucuronidation and sulfation conjugates. The most abundant metabolites included monohydroxylated products on the naphthalene ring, direct glucuronidation of the parent compound, and combined hydroxylation-glucuronidation products. . . ().

The primary metabolic transformations involve hydroxylation of the naphthalene and phenolic rings, reduction, and subsequent Phase II conjugation (glucuronidation and sulfation). These metabolic studies were conducted in the context of anti-doping research, as the World Anti-Doping Agency (WADA) prohibits exercise mimetics and metabolic modulators in competitive sports.

Research Dosing Context

Current Research Landscape

Comparison to Other Exercise Mimetics

SLU-PP-332 joins a growing class of pharmacological exercise mimetics that operate through distinct molecular targets. The landmark 2008 Cell paper by Narkar, Evans, and colleagues established GW501516 (a PPARdelta agonist) and AICAR (an AMPK activator) as the first compounds to demonstrate pharmacological enhancement of exercise endurance. . . (). Each compound targets a different node in the exercise signaling network:

• GW501516 (PPARdelta agonist): Synergizes with exercise training to increase oxidative myofibers and endurance. PPARdelta is a nuclear receptor that regulates fatty acid catabolism in muscle. However, GW501516 has attracted significant safety concerns due to reports of carcinogenicity in long-term preclinical studies, leading to abandonment of clinical development by GlaxoSmithKline.

• AICAR (AMPK activator): Activates AMP-activated protein kinase, a cellular energy sensor, and was shown to enhance running endurance by 44% in sedentary mice without any exercise training. AICAR has limited bioavailability and a short half-life, restricting its practical utility as a research tool for chronic studies.

• SLU-PP-332 (pan-ERR agonist): Targets the ERR nuclear receptor family, which is positioned upstream of many exercise-responsive gene networks. A distinguishing feature is its activation of the DDIT4-dependent acute aerobic exercise gene program, which was not reported for PPARdelta or AMPK agonists. . . (). This suggests that ERR agonism engages a qualitatively distinct subset of exercise-responsive pathways.

Additionally, SLU-PP-332’s ability to function as a caloric restriction mimetic in the aging kidney . . (). and to enhance cardiac function in heart failure . . (). suggests a broader therapeutic scope than exercise mimetics operating through more downstream targets.

Development of SLU-PP-915 and Next-Generation ERR Agonists

A significant advance in ERR pharmacology was the development of SLU-PP-915, a chemically distinct pan-ERR agonist with confirmed oral bioavailability. Published in 2026, studies demonstrated that SLU-PP-915 enhances aerobic exercise performance (distance and duration) to a comparable extent as SLU-PP-332 when administered intraperitoneally, and maintains similar efficacy when given orally, adjusted for systemic exposure. Both compounds robustly induce DDIT4 expression at levels matching or exceeding those induced by treadmill running. Notably, SLU-PP-915 synergizes with exercise training to further enhance mitochondrial gene expression, suggesting that pharmacological ERR activation and physical exercise engage complementary adaptive pathways. . . ().

Anti-Doping Significance

The exercise mimetic properties of SLU-PP-332 have attracted attention from anti-doping authorities. WADA’s Prohibited List includes exercise mimetics and metabolic modulators. Two independent 2026 studies — one from the German Sport University Cologne . . (). and one from the UCLA Olympic Analytical Laboratory . . (). — have comprehensively characterized SLU-PP-332’s metabolic transformation products using state-of-the-art liquid chromatography-high resolution mass spectrometry (LC-HRMS/MS). These studies identified numerous metabolites suitable as biomarkers for doping control, reflecting the reality that even preclinical research compounds may be obtained and misused for performance enhancement.

ERR Biology: Foundational and Emerging Research

The broader ERR research landscape continues to expand. The foundational role of ERRgamma as a key regulator of muscle mitochondrial activity and oxidative capacity was established by Rangwala and colleagues, who showed that muscle-specific ERRgamma transgenic mice had increased exercise capacity and mitochondrial enzyme activity, while ERRgamma heterozygous knockout mice showed decreased exercise capacity. . . (). Earlier work by Sladek, Bader, and Giguere in 1997 established ERRalpha as a transcriptional regulator of medium-chain acyl-CoA dehydrogenase (MCAD), a key enzyme in mitochondrial beta-oxidation of fatty acids, providing the first molecular link between ERRs and fatty acid metabolism. . . ().

Downstream of the ERR-PGC-1alpha axis, the tissue-specific regulator Perm1 (PGC-1- and ERR-induced regulator in muscle 1) has been identified as a key effector that regulates the expression of selective PGC-1alpha/ERR target genes in skeletal muscle. Silencing of Perm1 compromises respiratory capacity and diminishes PGC-1alpha-induced mitochondrial biogenesis, establishing it as a critical node in the ERR-mediated metabolic signaling cascade. . . ().

Molecular dynamics simulations of ligand pathways in the ERR family have revealed that different pathways to the ligand binding pocket are favored depending on the receptor subtype and conformational state, with agonists and antagonists utilizing distinct entry routes. These structural insights continue to inform the rational design of next-generation ERR-targeted compounds. . . ().

Safety & Tolerability

Preclinical Safety Data

The safety profile of SLU-PP-332 has been assessed through short-term mouse studies. In the initial characterization, mice administered SLU-PP-332 at 50 mg/kg twice daily by intraperitoneal injection for 10 days showed no overt toxicity. Complete blood counts and electrolyte panels were normal. Serum creatine kinase levels were not significantly altered, suggesting a lack of skeletal muscle toxicity despite the compound’s profound effects on muscle gene expression and physiology. . . ().

Longer-duration studies in the aging kidney model (8 weeks of treatment in 21-month-old mice) and the metabolic syndrome models (28 days of treatment) have been conducted without reports of significant adverse effects, though detailed toxicological assessments from these studies have not been the primary focus of the published reports. . . (). . . ().

Nuclear Receptor Selectivity

An important aspect of SLU-PP-332’s safety profile is its selectivity within the nuclear receptor superfamily. The compound does not alter the activity of estrogen receptors (ERalpha or ERbeta) or other nuclear receptors in cotransfection assays, reducing the risk of off-target endocrine effects. The approximately 4.4-fold selectivity for ERRalpha over ERRgamma, and approximately 2.3-fold selectivity over ERRbeta, means that at pharmacologically relevant doses all three ERR isoforms are engaged. This pan-agonist profile appears to be advantageous rather than problematic, as different tissues rely on different ERR isoforms for metabolic regulation, and the compound’s demonstrated efficacy across skeletal muscle (ERRalpha-dependent), heart (ERRgamma-dependent), and kidney (pan-ERR effects) supports the value of engaging the full receptor family. . . (). . . ().

Conclusion

SLU-PP-332 represents a significant advance in the pharmacology of exercise mimetics and the broader field of metabolic therapeutics. As the first synthetic compound to achieve potent agonism of ERRalpha — a receptor previously considered an intractable drug target — it has opened a new avenue for investigating the therapeutic potential of ERR activation. The compound’s ability to induce an acute aerobic exercise gene program, enhance exercise endurance in sedentary mice, reduce obesity and metabolic syndrome, protect against heart failure, reverse age-related kidney decline, and restore the metabolic profile of aged human myoblasts demonstrates the remarkable breadth of ERR-regulated physiology.

The development trajectory from SLU-PP-332 to SLU-PP-915 illustrates the iterative process of chemical tool development: the initial compound validated the target and established proof of concept, while the next-generation analog addresses the pharmacokinetic limitation of oral bioavailability. Both compounds continue to serve as valuable chemical probes for dissecting ERR biology and as starting points for potential therapeutic development.

Key questions for ongoing research include the long-term safety profile of chronic ERR activation, the optimal dosing strategies for different disease contexts, the potential for synergy between ERR agonists and physical exercise or dietary interventions, and the translation of preclinical findings to human physiology. The convergence of evidence from multiple independent laboratories and disease models provides a strong foundation for continued investigation of ERR agonism as a pharmacological strategy to combat metabolic disease, muscle dysfunction, and the metabolic consequences of aging and physical inactivity.

References

The studies referenced throughout this monograph represent a selection of the published literature on SLU-PP-332 and ERR biology. For the most current publications, researchers are encouraged to search PubMed using the terms “SLU-PP-332,” “ERR agonist exercise mimetic,” “estrogen-related receptor agonist,” “SLU-PP-915,” or “pan-ERR agonist” for updated findings.